Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Diese Studie ist ein nicht-interventionelles Krankheitsregister für jugendliche und erwachsene Patienten mit atopischer Dermatitis, die eine systemische Behandlung beginnen oder umstellen (ARMADA-AD)

30. Oktober 2026 aktualisiert von: Sanofi

Atopische Dermatitis Krankheitsregister für erwachsene und jugendliche Patienten, die eine systemische Behandlung beginnen oder umstellen

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.

The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.

Studienübersicht

Status

Rekrutierung

Bedingungen

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Trial Transparency email recommended (Toll free for US & Canada)
  • Telefonnummer: option 6 800-633-1610
  • E-Mail: Contact-US@sanofi.com

Studienorte

  • China
      • Chongqing, China, 400016
        • Rekrutierung
        • The First Affiliated Hospital of Chongqing Medical University-Site Number : 1560011
        • Kontakt:
        • Hauptermittler:
          • Tao Cai
      • Shanghai, China, 200040
        • Rekrutierung
        • Huashan Hospital, Fudan University-Site Number: 1560012
        • Hauptermittler:
          • Wei Li
        • Kontakt:
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100191
        • Rekrutierung
        • Peking University Third Hospital-Site Number: 1560008
        • Hauptermittler:
          • Wenhui Wang
        • Kontakt:
    • Guangdong
      • Shenzhen, Guangdong, China, 518033
        • Rekrutierung
        • The Eighth Affiliated Hospital, Sun Yat-sen University-Site Number: 1560006
        • Kontakt:
        • Hauptermittler:
          • Peimei Zhou
    • Hu'nan
      • Changsha, Hu'nan, China, 410008
        • Rekrutierung
        • Xiangya Hospital of Central South University-Site Number : 1560001
        • Hauptermittler:
          • Juan Su
        • Kontakt:
      • Changsha, Hu'nan, China, 410011
        • Rekrutierung
        • The Second Xiangya Hospital of Central South University-Site Number: 1560014
        • Hauptermittler:
          • Yunsheng Liang
        • Kontakt:
    • Shanxi
      • Xi’an, Shanxi, China, 710004
        • Rekrutierung
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)-Site Number: 1560002
        • Hauptermittler:
          • Songmei Geng
        • Kontakt:
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Rekrutierung
        • West China Hospital, Sichuan University- Site Number: 1560003
        • Hauptermittler:
          • Jingyi Li
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310006
        • Rekrutierung
        • Hangzhou First People's Hospital-Site Number: 1560004
        • Hauptermittler:
          • Liming Wu
        • Kontakt:
      • Hangzhou, Zhejiang, China, 310009
        • Rekrutierung
        • The Second Affiliated Hospital of Zhejiang University School of Medicine-Site Number: 1560007
        • Hauptermittler:
          • Xiaoyong Man
        • Kontakt:
      • Ningbo, Zhejiang, China, 315010
        • Rekrutierung
        • The First Affiliated Hospital of Ningbo University-Site Number : 1560009
        • Kontakt:
        • Hauptermittler:
          • Bingjiang Lin
  • Frankreich
    • Doubs
      • Besançon, Doubs, Frankreich, 25030
        • Rekrutierung
        • CHU Besançon - Hôpital Jean Minjoz-Site Number: 2500010
        • Hauptermittler:
          • Francois Aubin
        • Kontakt:
    • Drome
      • Valence, Drome, Frankreich, 26000
        • Rekrutierung
        • Centre Hospitalier de Valence-Site Number: 2500005
        • Kontakt:
        • Hauptermittler:
          • Anne Grange
    • Haut Rhin
      • Mulhouse, Haut Rhin, Frankreich, 68100
        • Rekrutierung
        • GHRMSA - Hospital Emile Muller-Site Number : 2500006
        • Kontakt:
        • Hauptermittler:
          • Catherine Michel
    • Reunion
      • Saint-Pierre, Reunion, Frankreich, 97448
        • Rekrutierung
        • CHU de La Reunion-Site Number: 2500007
        • Hauptermittler:
          • Antoine Bertolotti
        • Kontakt:
          • Antoine Bertolotti
    • Rhone
      • Romans-sur-Isère, Rhone, Frankreich, 26102
        • Rekrutierung
        • Hopitaux Drome Nord-Site Number : 2500002
        • Hauptermittler:
          • Francois Skowron
        • Kontakt:
    • Saone Et Loire
      • Chalon-sur-Saône, Saone Et Loire, Frankreich, 71100
        • Rekrutierung
        • Centre Hospitalier William Morey-Site Number: 2500008
        • Kontakt:
        • Hauptermittler:
          • Marie Dhers
    • Sarthe
      • Le Mans, Sarthe, Frankreich, 72037
        • Rekrutierung
        • Centre Hospitalier du Mans-Site Number: 2500004
        • Kontakt:
        • Hauptermittler:
          • Nathalie Beneton Benhard
  • Italien
      • Ancona, Italien, 60126
        • Rekrutierung
        • Azienda Ospedaliero Universitaria delle Marche-Site Number: 3800009
        • Hauptermittler:
          • Oriana Simonetti
        • Kontakt:
      • Novara, Italien, 28100
        • Rekrutierung
        • Ospedale Maggiore di Novara-Site Number: 3800005
        • Kontakt:
        • Hauptermittler:
          • Paola Savoia
      • Reggio Emilia, Italien, 42100
        • Rekrutierung
        • Arcispedale Santa Maria Nuova Azienda Ospedaliera di Reggio Emilia-Site Number : 3800006
        • Kontakt:
        • Hauptermittler:
          • Vito Di Lernia
      • Roma, Italien, 00144
        • Rekrutierung
        • Istituto San Gallicano IRCCS - Istituti Fisioterapici Ospitalieri-Site Number: 3800002
        • Kontakt:
        • Hauptermittler:
          • Maria Concetta Fargnoli
  • Japan
    • Kagawa-ken
      • Marugame-shi, Kagawa-ken, Japan, 763-0074
        • Rekrutierung
        • Takeoka Dermatology Clinic- Site Number : 3920005
        • Kontakt:
        • Hauptermittler:
          • Shintaro Takeoka
    • Osaka
      • Habikino-shi, Osaka, Japan, 583-8588
        • Rekrutierung
        • Osaka Habikino Medical Center-Site Number : 3920001
        • Hauptermittler:
          • Yoko Kataoka
        • Kontakt:
    • Shizuoka
      • Hamamatsu, Shizuoka, Japan, 430-0929
        • Rekrutierung
        • JA-Shizuoka Enshu Hospital-Site Number: 3920003
        • Kontakt:
        • Hauptermittler:
          • Chika Shibuya
  • Kanada
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4V 1R9
        • Rekrutierung
        • Origins Dermatology Centre-Site Number : 1240003
        • Hauptermittler:
          • Rachel Asiniwasis
        • Kontakt:
  • Saudi-Arabien
      • Jeddah, Saudi-Arabien, 21452
        • Rekrutierung
        • Erfan and Bagedo Hospital-Site Number : 6820002
        • Kontakt:
        • Hauptermittler:
          • Ahmed Ismail Ebraheem Abdellateef
      • Jeddah, Saudi-Arabien, 23421
        • Rekrutierung
        • Medical Fakeeh-Site Number : 6820003
        • Kontakt:
        • Hauptermittler:
          • Ayman Elgendi
      • Riyadh, Saudi-Arabien, 12231
        • Rekrutierung
        • King Fahad Medical City-Site Number : 6820001
        • Kontakt:
        • Hauptermittler:
          • Mohammed Alajlan
  • Spanien
      • Alicante, Spanien, 03010
        • Rekrutierung
        • Hospital General Universitario Dr. Balmis-Site Number: 7240005
        • Hauptermittler:
          • Juan Francisco Silvestre Salvador
        • Kontakt:
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Spanien, 08041
        • Rekrutierung
        • Investigational Site Number : 7240006
    • Tenerife
      • Santa Cruz de Tenerife, Tenerife, Spanien, 38320
        • Rekrutierung
        • Hospital Universitario de Canarias-Site Number: 7240008
        • Hauptermittler:
          • Ruperto Gonzalez Perez
        • Kontakt:
  • Vereinigte Arabische Emirate
      • Abu Dhabi, Vereinigte Arabische Emirate, 66566
        • Rekrutierung
        • Mediclinic Hospital, AUH-Site Number: 7840004
        • Kontakt:
        • Hauptermittler:
          • Hussein Abdel Dayem
      • Abu Dhabi, Vereinigte Arabische Emirate, 6222
        • Rekrutierung
        • NMC Specialty Hospital-Site Number : 7840002
        • Kontakt:
        • Hauptermittler:
          • Ahmed Ameen
      • Al Karama, Vereinigte Arabische Emirate, 50730
        • Rekrutierung
        • Dr Joseph Polyclinic Amber Clinic-Site Number: 7840005
        • Kontakt:
        • Hauptermittler:
          • Srikumar Goturu
      • Dubai, Vereinigte Arabische Emirate, 00000
        • Rekrutierung
        • Dermatology and Aesthetic Center Rashid Hospital-Site Number : 7840003
        • Kontakt:
        • Hauptermittler:
          • Amani Abdulla Rahma Alfalasi
  • Vereinigte Staaten
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35244
        • Rekrutierung
        • Cahaba Dermatology & Skin Health Center- Site Number : 8400006
        • Hauptermittler:
          • Vlada Groysman
        • Kontakt:
      • Montgomery, Alabama, Vereinigte Staaten, 36117
        • Rekrutierung
        • River Region Dermatology and Laser- Site Number : 8400041
        • Hauptermittler:
          • Porcia Love
        • Kontakt:
    • Arizona
      • Gilbert, Arizona, Vereinigte Staaten, 85234
        • Rekrutierung
        • San Tan Allergy & Asthma- Site Number : 8400031
        • Kontakt:
        • Hauptermittler:
          • Sam Reed Shimamoto
      • Phoenix, Arizona, Vereinigte Staaten, 85008
        • Rekrutierung
        • Saguaro Dermatology- Site Number : 8400028
        • Hauptermittler:
          • Dathan Hamann
        • Kontakt:
    • California
      • Bakersfield, California, Vereinigte Staaten, 93301
        • Rekrutierung
        • Kern Research, Inc.- Site Number : 8400047
        • Hauptermittler:
          • Tonny Tanus
        • Kontakt:
      • Fremont, California, Vereinigte Staaten, 94538
        • Rekrutierung
        • Center for Dermatology Clinical Research- Site Number : 8400014
        • Hauptermittler:
          • Sunil Dhawan
        • Kontakt:
      • Los Angeles, California, Vereinigte Staaten, 90045
        • Rekrutierung
        • Dermatology Research Associates - Los Angeles- Site Number : 8400020
        • Hauptermittler:
          • Howard Sofen
        • Kontakt:
      • Northridge, California, Vereinigte Staaten, 91325
        • Rekrutierung
        • Northridge Clinical Trials, LLC- Site Number : 8400009
        • Hauptermittler:
          • Navid Ezra
        • Kontakt:
      • Oakland, California, Vereinigte Staaten, 94596
        • Rekrutierung
        • Sunwise Clinical Research, LLC.- Site Number : 8400010
        • Kontakt:
        • Hauptermittler:
          • Michael Abdel Malek
      • Pomona, California, Vereinigte Staaten, 91767
        • Rekrutierung
        • Empire Clinical Research, LLC- Site Number : 8400007
        • Kontakt:
          • Usha Mantha
        • Hauptermittler:
          • Usha Mantha
      • San Diego, California, Vereinigte Staaten, 92123
        • Rekrutierung
        • University Clinical Trials- Site Number : 8400019
        • Hauptermittler:
          • Walter Nahm
        • Kontakt:
    • Colorado
      • Wheat Ridge, Colorado, Vereinigte Staaten, 80033
        • Rekrutierung
        • Western States Clinical Research, Inc.- Site Number : 8400051
        • Hauptermittler:
          • Jeffrey Rumbyrt
        • Kontakt:
    • Florida
      • Doral, Florida, Vereinigte Staaten, 33172
        • Rekrutierung
        • St. Jude Clinical Research- Site Number : 8400049
        • Kontakt:
        • Hauptermittler:
          • Gustavo Torres
      • North Miami Beach, Florida, Vereinigte Staaten, 33162-4708
        • Rekrutierung
        • Ziaderm Research, LLC- Site Number : 8400021
        • Hauptermittler:
          • Tory Sullivan
        • Kontakt:
    • Georgia
      • Macon, Georgia, Vereinigte Staaten, 31217
        • Rekrutierung
        • Skin Care Physicians of Georgia - Macon- Site Number : 8400034
        • Hauptermittler:
          • David Cohen
        • Kontakt:
    • Illinois
      • Normal, Illinois, Vereinigte Staaten, 61761
        • Rekrutierung
        • Sneeze, Wheeze, & Itch Associates, LLC- Site Number : 8400029
        • Hauptermittler:
          • Dareen Siri
        • Kontakt:
      • North Chicago, Illinois, Vereinigte Staaten, 60064
        • Rekrutierung
        • Rosalind Franklin University of Medicine and Science- Site Number: 8400056
        • Hauptermittler:
          • Raj Chovatiya
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48103
        • Rekrutierung
        • David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017
        • Hauptermittler:
          • David Fivenson
        • Kontakt:
      • Auburn Hills, Michigan, Vereinigte Staaten, 48326
        • Rekrutierung
        • Oakland Hills Dermatology- Site Number : 8400042
        • Hauptermittler:
          • Christofer Buatti
        • Kontakt:
      • Bay City, Michigan, Vereinigte Staaten, 48706
        • Rekrutierung
        • Great Lakes Research Group - Bay City- Site Number : 8400052
        • Hauptermittler:
          • Brent Boyce
        • Kontakt:
      • Caledonia, Michigan, Vereinigte Staaten, 49316
        • Rekrutierung
        • The Derm Institute of West Michigan- Site Number : 8400025
        • Hauptermittler:
          • Kristi Hawley
        • Kontakt:
        • Kontakt:
      • Detroit, Michigan, Vereinigte Staaten, 48201
        • Rekrutierung
        • Wayne State University - Detroit Medical Center- Site Number : 8400035
        • Hauptermittler:
          • Steven Daveluy
        • Kontakt:
      • Waterford, Michigan, Vereinigte Staaten, 48328
    • Missouri
      • Bolivar, Missouri, Vereinigte Staaten, 65613
        • Rekrutierung
        • Red River Research Partners, Llc- Site Number : 8400054
        • Kontakt:
        • Hauptermittler:
          • Murphy Mastin
      • Kirksville, Missouri, Vereinigte Staaten, 63501
        • Rekrutierung
        • Cleaver Dermatology- Site Number : 8400033
        • Kontakt:
        • Hauptermittler:
          • David Cleaver
    • Nebraska
      • Lincoln, Nebraska, Vereinigte Staaten, 68510
        • Rekrutierung
        • Allergy Asthma & Immunology- Site Number : 8400044
        • Hauptermittler:
          • Robert Szalewski
        • Kontakt:
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89144
        • Rekrutierung
        • Las Vegas Dermatology- Site Number : 8400002
        • Hauptermittler:
          • Harry Greenberg
        • Kontakt:
    • New Hampshire
      • Portsmouth, New Hampshire, Vereinigte Staaten, 03801
        • Rekrutierung
        • Optima Research Portsmouth- Site Number : 8400032
        • Hauptermittler:
          • Abel Jarell
        • Kontakt:
    • New Mexico
      • Albuquerque, New Mexico, Vereinigte Staaten, 87106
        • Rekrutierung
        • University Of New Mexico School Of Medicine- Site Number : 8400022
    • North Carolina
      • Huntersville, North Carolina, Vereinigte Staaten, 28078
        • Rekrutierung
        • Piedmont Plastic Surgery and Dermatology- Site Number : 8400038
        • Kontakt:
        • Hauptermittler:
          • Nicole Seminara Zambrzycka
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27104
        • Rekrutierung
        • Wake Forest University Health Sciences- Site Number : 8400003
        • Hauptermittler:
          • Steven Feldman
        • Kontakt:
    • North Dakota
      • Fargo, North Dakota, Vereinigte Staaten, 58103
        • Rekrutierung
        • Red River Research Partners - Fargo- Site Number : 8400037
        • Hauptermittler:
          • Michael Blankinship
        • Kontakt:
    • Ohio
      • Marion, Ohio, Vereinigte Staaten, 43302
        • Rekrutierung
        • Dermatology Associates of Mid-Ohio- Site Number : 8400026
        • Kontakt:
          • George Scott Drew
          • Telefonnummer: 740-244-8559
          • E-Mail: spfxv@aol.com
        • Hauptermittler:
          • George Scott Drew
      • Mason, Ohio, Vereinigte Staaten, 45040
        • Rekrutierung
        • Dermatologists of Southwest Ohio - Mason- Site Number : 8400050
        • Hauptermittler:
          • Rocco Serrao
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
        • Rekrutierung
        • UPMC - Department of Dermatology- Site Number : 8400024
        • Hauptermittler:
          • Joe Tung
        • Kontakt:
    • Rhode Island
      • Warwick, Rhode Island, Vereinigte Staaten, 02886
        • Rekrutierung
        • Care Access Research - Warwick 2- Site Number : 8400045
        • Kontakt:
        • Hauptermittler:
          • John Zwetchkenbaum
    • South Carolina
      • Spartanburg, South Carolina, Vereinigte Staaten, 29307
        • Rekrutierung
        • Advanced Dermatology and Cosmetic Surgery - Spartanburg- Site Number : 8400004
        • Kontakt:
        • Hauptermittler:
          • Amylynne Frankel
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75235
        • Rekrutierung
        • Reveal Research Institute - Dallas- Site Number : 8400012
        • Hauptermittler:
          • Aaron Farberg
        • Kontakt:
      • Fort Worth, Texas, Vereinigte Staaten, 76244
        • Abgeschlossen
        • Innovate Research - Fort Worth- Site Number : 8400016
      • Pflugerville, Texas, Vereinigte Staaten, 78660
        • Rekrutierung
        • Austin Institute for Clinical Research, Inc- Site Number : 8400030
        • Hauptermittler:
          • Edward Lain
        • Kontakt:
      • Sugar Land, Texas, Vereinigte Staaten, 77479
        • Rekrutierung
        • Complete Dermatology - Sugar Land- Site Number : 8400001
        • Hauptermittler:
          • Bartley Gill
        • Kontakt:
    • Utah
      • Bountiful, Utah, Vereinigte Staaten, 84010
        • Rekrutierung
        • Cope Family Medicine - Ogden Clinic- Site Number : 8400053
      • Springville, Utah, Vereinigte Staaten, 84663
        • Rekrutierung
        • Springville Dermatology - Springville- Site Number : 8400055
        • Kontakt:
        • Hauptermittler:
          • Michael Peterson
    • Virginia
      • Falls Church, Virginia, Vereinigte Staaten, 22042
        • Rekrutierung
        • Fuchs Dermatology- Site Number : 8400027
        • Kontakt:
        • Hauptermittler:
          • Aaron Fuchs
    • Washington
      • Mill Creek, Washington, Vereinigte Staaten, 98012
        • Rekrutierung
        • Frontier Dermatology Partners CRO LLC- Site Number : 8400011
        • Kontakt:
        • Hauptermittler:
          • Eingun James Song
      • Seattle, Washington, Vereinigte Staaten, 98105
        • Rekrutierung
        • University of Washington - Roosevelt Location- Site Number : 8400005
        • Kontakt:
        • Hauptermittler:
          • Vivian Shi

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

12 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients with any atopic dermatitis severity will be invited to enroll in the registry after the decision has been made to initiate a new systemic medication for the first time or switch systemic therapies. Inclusion in the registry will not influence a patient's treatment course.

Beschreibung

Inclusion Criteria:

  • Patients aged more than or equal to (≥) 12 years at the time of consent.
  • Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20.
  • Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil)
  • Signed informed consent for registry participation by the patient or parent/legal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up.

Exclusion Criteria:

  • Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care.
  • Insufficient understanding of the study by the patient and/or parent/guardian.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Atopic Dermatitis

This study plans to collect information on adolescent and adult patients with atopic dermatitis who initiate or switch any systemic treatment (eg, biologics, oral Janus kinase [JAK] inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) for AD according to the country-specific prescribing information. During the study, investigators will prescribe medical products for treatment of AD per standard of care (SoC) and per medical judgment.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants Utilizing Atopic Dermatitis (AD) Treatment
Zeitfenster: Baseline to up to 60 months

The number (and percentage) of participants taking AD treatments and treatments per patient will be described.
Baseline to up to 60 months
Duration of Treatment
Zeitfenster: Baseline to up to 60 months

The duration of AD treatments will be summarized descriptively.
Baseline to up to 60 months
AD Treatment Sequences
Zeitfenster: Baseline to up to 60 months

The ordering of AD treatments will be summarized descriptively.
Baseline to up to 60 months
Number of Participants Initiating AD Treatments with Reasons
Zeitfenster: Baseline to up to 60 months

The number (and percentage) of patients initiating AD treatment and reasons for initiation will be summarized descriptively.
Baseline to up to 60 months
Number of Participants Interrupting AD Treatment
Zeitfenster: Baseline to up to 60 months

The number (and percentage) of patients interrupting AD treatment and reasons for treatment interruption will be summarized descriptively.
Baseline to up to 60 months
Number of Participants Discontinuing AD Treatment
Zeitfenster: Baseline to up to 60 months

The number (and percentage) of patients discontinuing AD treatment and reasons for treatment discontinuation will be summarized descriptively.
Baseline to up to 60 months
Number of Participants Switching AD Treatments
Zeitfenster: Baseline to up to 60 months

The number (and percentage) of patients switching AD treatment and reasons for treatment switch will be summarized descriptively.
Baseline to up to 60 months
Number of Participants Augmenting AD treatment
Zeitfenster: Baseline to up to 60 months

The number (and percentage) of patients augmenting AD treatment will be summarized descriptively.
Baseline to up to 60 months
Number of Participants Modifying AD Treatment Dose
Zeitfenster: Baseline to up to 60 months

The number (and percentage) of patients modifying AD treatment dose, reasons for dose modification, and dosing will be summarized descriptively.
Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Eczema Area and Severity Index (EASI)
Zeitfenster: Baseline to up to 60 months

Clinical outcomes measured using EASI will be summarized at the start of a treatment episode and each follow-up time point.
Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Body Surface Area (BSA)
Zeitfenster: Baseline to up to 60 months

Clinical outcomes measured using BSA will be summarized at the start of a treatment episode and each follow-up time point.
Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD)
Zeitfenster: Baseline to up to 60 months

Clinical outcomes measured using vIGA-AD will be summarized at the start of a treatment episode and each follow-up time point.
Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Revised Investigator's Global Assessment for Atopic Dermatitis (rIGA-AD)
Zeitfenster: Baseline to up to 60 months

Clinical outcomes measured using rIGA-AD will be summarized at the start of a treatment episode and each follow-up time point.
Baseline to up to 60 months
Change in Atopic Dermatitis Control Test (ADCT) from Baseline
Zeitfenster: Baseline to up to 60 months

The ADCT is a 6-item patient-reported outcomes instrument with a 7-day recall period to measure AD disease control. Total score ranges from 0 to 24.
Baseline to up to 60 months
Change in Patient Global Impression of Severity (PGIS) from Baseline
Zeitfenster: Baseline to up to 60 months

The PGIS is a single item tool used to assess current severity of eczema symptoms, scored on a 5-point scale from 1 = no symptoms to 5 = very severe symptoms.
Baseline to up to 60 months
Change in Itch severity as Measured with the Peak Pruritus Numeric Rating Scale (PP-NRS) from Baseline
Zeitfenster: Baseline to up to 60 months

The PP-NRS is a single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours, with 0 = no itch and 10 = worst itch imaginable.
Baseline to up to 60 months
Change in Skin Pain as Measured with Skin Pain Numeric Rating Scale (SP-NRS) from Baseline
Zeitfenster: Baseline to up to 60 months

The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD during the past 24 hours, with 0 = no pain and 10 = worst possible pain imaginable.
Baseline to up to 60 months
Change in Sleep Disturbance as Measured with Sleep Disturbance Numeric Rating Scale (SD-NRS) from Baseline
Zeitfenster: Baseline to up to 60 months

The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD, with 0 being 'no sleep loss related to the symptoms of atopic dermatitis' and 10 being 'I did not sleep at all' due to the symptoms of atopic dermatitis.
Baseline to up to 60 months
Remission of AD
Zeitfenster: Baseline to up to 60 months

Total remission of all signs and symptoms of AD will be assessed.
Baseline to up to 60 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Sociodemographic characteristics of Participants
Zeitfenster: Baseline

Demographics characteristics including age, sex, body weight, height, geographic region, education level, employment status, smoking and alcohol status will be collected.
Baseline
Ethnic Origin in Combination with Fitzpatrick Scale
Zeitfenster: Baseline

The Fitzpatrick Skin Type Scale was developed based on an individual's reaction to sun exposure and will be completed by the Investigator. Skin types range from I - VI, with scores of I indicating the palest skin tone with no inherent melanin pigmentation, and VI indicating the darkest skin tone with significant amount of melanin.
Baseline
Disease characteristics of Participants
Zeitfenster: Baseline

History of AD (including date of diagnosis, age of onset, specialty of provider who diagnosed condition), AD morphology, including but not limited to, patches, plaques, prurigo nodules, lichenoid papules, perifollicular papules, nummular lesions, and psoriasiform lesions and family history of AD and comorbidities will be collected.
Baseline
Change from Baseline in Dermatology-specific Quality of Life Measure with Dermatology Life Quality Index (DLQI)
Zeitfenster: Baseline to up to 60 months

DLQI is calculated by summing the score of each question resulting in a maximum score of 30 and a minimum score of 0 (higher scores indicate quality of life is more impaired).
Baseline to up to 60 months
Change from Baseline in Dermatology-specific Quality of Life Measure with Children's Dermatology Life Quality Index (CDLQI)
Zeitfenster: Baseline to up to 60 months

The CDLQI is calculated by summing the score of each question resulting in a maximum score of 30 and a minimum score of 0 (higher scores indicate quality of life is more impaired).
Baseline to up to 60 months
Change from Baseline in Burden of Assessment Using Patient Health Questionnaire-9 (PHQ-9)
Zeitfenster: Baseline to up to 60 months

PHQ-9 is a 9-item, validated, patient-reported questionnaire to assess depression which scores each of the 9 Diagnostic and Statistical Manual of Mental Disorders-IV criteria as "0" (not at all) to "3" (nearly every day). Possible scores range from 0 to 27 and are classified as 1-4: "minimal depression"; 5-9: "mild depression"; 10-14: "moderate depression"; 15-19: "moderately severe depression"; and 20-27: "severe depression".
Baseline to up to 60 months
Change from Baseline in AD Specific Work and Classroom Productivity and Impairment Assessed Using WPAI+CIQ
Zeitfenster: Baseline to up to 60 months

Work Productivity and Activity Impairment plus Classroom Impairment Questions (WPAI+CIQ) is a 10-item, patient-reported, validated questionnaire adapted for AD to measure impairments in work, classroom, and regular daily activities over a 7-day period.
Baseline to up to 60 months
Change from Baseline in Treatment Satisfaction Assessed Using Treatment Satisfaction Questionnaire for Medication (TSQM-9)
Zeitfenster: Baseline to up to 60 months

The 14-item TSQM-9 is a generic measure of treatment satisfaction, assessing side effects, effectiveness, convenience and global satisfaction, over the last 2 to 3 weeks, or since the patient has last used it. A lower score indicates lower satisfaction with treatment.
Baseline to up to 60 months
Visits with Specialty of Attending Healthcare Provider and Reason for Visit
Zeitfenster: Baseline to up to 60 months

Health care resource utilization including visits with specialty of attending health care provider and reason for visit (example, disease flare-up, regular visit, prescription change, adverse event [AE]) will be assessed.
Baseline to up to 60 months
Hospitalizations for AD
Zeitfenster: Baseline to up to 60 months

Hospitalization for AD will be assessed.
Baseline to up to 60 months
Prevalence of Comorbid Atopic Conditions
Zeitfenster: Baseline to up to 60 months

Prevalence of comorbid atopic conditions (including but not limited to, asthma, allergic conjunctivitis, allergic rhinitis, eosinophilic esophagitis, nasal polyposis, food allergy, prurigo nodularis, chronic spontaneous urticaria, and rhinoconjunctivitis) and non-atopic conditions (including but not limited to, insomnia, anxiety, attention deficit disorder, depression, major adverse cardiovascular event, cardiovascular disease, skin infection, pulmonary disease, osteoporosis, fractures, contact allergy, and inflammatory conditions) will be assessed.
Baseline to up to 60 months
Incidence of Comorbid Atopic Conditions
Zeitfenster: Baseline to up to 60 months

Incidence of comorbid atopic conditions (including but not limited to, asthma, allergic conjunctivitis, allergic rhinitis, eosinophilic esophagitis, nasal polyposis, food allergy, prurigo nodularis, chronic spontaneous urticaria, and rhinoconjunctivitis) and non-atopic conditions (including but not limited to, insomnia, anxiety, attention deficit disorder, depression, major adverse cardiovascular event, cardiovascular disease, skin infection, pulmonary disease, osteoporosis, fractures, contact allergy, and inflammatory conditions) will be assessed.
Baseline to up to 60 months
Change from Baseline in Asthma Control Assessed with Asthma Control Questionnaire-5 (ACQ-5)
Zeitfenster: Baseline to up to 60 months

ACQ-5 is a 5-item questionnaire used to assess asthma control [33]. Each question is rated on a 7-point scale (0=no impairment; 6=maximum impairment). The ACQ-5 score is calculated using the mean of the 5 items and ranges between 0 (well controlled asthma) to 6 (extremely poorly controlled asthma). The ACQ-5 will only be completed by patients with comorbid asthma.
Baseline to up to 60 months
Occurrence of Concomitant Medication use for AD and Selected Comorbidities
Zeitfenster: Baseline to up to 60 months

The occurrence of concomitant medication use for AD and selected comorbidities at baseline and changes (including reason for change) will be summarized.
Baseline to up to 60 months
Number of Adverse Events (SAEs)
Zeitfenster: Baseline to up to 60 months

Number of patients experiencing AEs.
Baseline to up to 60 months
Number of Serious Adverse Events (SAEs)
Zeitfenster: Baseline to up to 60 months

Number of patients experiencing SAEs.
Baseline to up to 60 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Sanofi

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. November 2025

Primärer Abschluss (Geschätzt)

30. Januar 2034

Studienabschluss (Geschätzt)

30. Januar 2034

Studienanmeldedaten

Zuerst eingereicht

28. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. Dezember 2025

Zuerst gepostet (Tatsächlich)

18. Dezember 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • OBS18388
  • U1111-1311-1824 (Registrierungskennung: ICTRP)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren